Cytogen (US) begins OncoScint breast cancer trials
This article was originally published in Clinica
Executive Summary
Cytogen (US) has begun clinical trials of its OncoScint CR/OV imaging agent for use in pre-operative breast cancer staging. The only FDA-approved monoclonal antibody-based tumour imaging agent, OncoScint CR/OV is indicated for colorectal and ovarian cancer. The multi-centre breast cancer trial aims to confirm the agent's ability to detect axillary lymph node metastases. In a 20-patient study at the Italian National Cancer Institute in Milan, the agent had a sensitivity of 91% in detecting axillary lymph node involvement in mastectomy candidates.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.